Based on its unique properties SVec is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company we formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene therapy fields of research. With major regulatory, legal and intellectual property firms, we are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.